CompaniesLevo Therapeutics

Levo Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

3

As Collaborator

1

Total Enrollment

288

By Phase

PHASE1: 2PHASE2: 1PHASE3: 1

By Status

COMPLETED: 2WITHDRAWN: 1RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
NCT03649477
NCT03983954
NCT04880863
NCT05894447
Hover over trial bars to see details

Recent Trials

NCT05894447Collaborator
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
PHASE1Withdrawn
Started: Nov 30, 2023 · Completed: Jun 30, 2028
NCT04880863Lead Sponsor
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
PHASE2Completed
38 participants
Started: Oct 26, 2021 · Completed: Jan 30, 2024
NCT03983954Lead Sponsor
Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
PHASE1Recruiting
120 participants
Started: Oct 10, 2019 · Completed: Mar 1, 2027
NCT03649477Lead Sponsor
Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
PHASE3Completed
130 participants
Started: Nov 20, 2018 · Completed: Jul 9, 2022
Funding History (2)
D
Nov 25, 2019
Filing
D
Nov 25, 2019
Filing